Clonal hematopoiesis refers to the somatic mutations in hematopoietic stem cells that lead to the expansion of mutated clones within peripheral blood. This phenomenon, often silent, has been linked to a drastically increased probability of developing leukemia and other blood cancers. Moreover, evidence accumulated over recent years indicates a robust association between CH and adverse cardiovascular outcomes, including coronary artery disease, heart failure, and arrhythmias. The most frequently mutated driver genes implicated in CH, namely DNMT3A, TET2, and ASXL1, represent approximately 80% of cases and reflect the mutational landscape influenced by aging hematopoiesis.

Importantly, epidemiological studies have demonstrated that the prevalence of clonal hematopoiesis rises exponentially with age; over 10% of people aged 70 years and older harbor one or more of these mutations. Given this high prevalence and the significant health risks linked with CH, researchers have prioritized understanding factors that modulate clonal expansion. The current study focuses on addressing whether colchicine, a historically well-established anti-inflammatory drug primarily used to treat gout, could influence the growth dynamics of CH clones.

The LoDoCo2 trial, originally designed to test colchicine’s efficacy in reducing cardiovascular events in patients with chronic coronary disease, revealed a substantial 31% relative risk reduction in cardiovascular incidents with a daily 0.5 mg dose of colchicine. Building on these findings, the current subanalysis interrogated longitudinal blood samples from trial participants to assess the drug’s potential impact on the clonal architecture of hematopoietic mutations over time. Specifically, four sequential blood draws were performed: baseline, 30 days post-randomization, one year, and at the conclusion of the study.

Using next-generation sequencing technology, researchers quantified the burden and allelic fraction of key CH mutations across these time points. Additionally, inflammation biomarkers in the blood, which have been implicated in both clonal expansion and atherogenesis, were assayed during the initial three time points. The study’s advanced genomic and biomarker profiling provided a multidimensional perspective on how anti-inflammatory therapy intersects with genetic and cellular alterations in aging blood.

The results revealed that individuals receiving colchicine exhibited a markedly reduced rate of clonal expansion compared to placebo recipients. While placebo-treated participants showed a significant 14.9% increase annually in overall CH clone size, those on colchicine experienced a non-significant rise of merely 6.3% per year. Notably, this growth attenuation was especially pronounced for TET2-mutated clones. The TET2 clone size increased by only 9.1% annually among the colchicine group, contrasting sharply with a 29.6% increase in the placebo group, suggesting a specific vulnerability of TET2-mutated hematopoietic cells to anti-inflammatory mechanisms.

Michael Honigberg, MD, MPP, FACC, the study’s senior author and a cardiologist at Massachusetts General Hospital, emphasized the clinical relevance of these findings. Larger CH clones have consistently correlated with higher risks of cardiovascular disease and malignancy, with TET2 mutations linked particularly closely to increased cardiovascular risk. This study not only elucidates colchicine’s multifaceted benefits in reducing cardiovascular events but also raises the possibility that the drug may interrupt the pathogenetic expansion of deleterious clonal blood populations.

In a complementary investigation also published in JACC and unveiled at ESC Congress 2025, researchers examined the relationship between CH and cardiovascular disease risk specifically in an elderly female cohort. The Women’s Health Initiative Long Life Study enrolled over 6,600 women, with a median age of 80, to probe whether the impact of clonal hematopoiesis wanes in advanced age as some prior research suggested. Contradicting earlier assumptions, this study found that several CH subtypes, including TET2, ASXL1, and JAK2 mutations, were indeed associated with increased incident cardiovascular disease in these older women.

This finding confirms that clonal hematopoiesis remains a critical contributor to cardiovascular health and disease progression well into late adulthood. Such insights underscore the enduring need to consider CH when evaluating cardiovascular risk profiles among the elderly, a demographic population growing rapidly worldwide. The mechanistic links between inflammation, aging hematopoiesis, and vascular pathology are increasingly recognized as fertile ground for therapeutic intervention.

Editorial leadership from Harlan Krumholz, MD, FACC, Editor-in-Chief of JACC and Harold H. Hines Jr Professor of Medicine at Yale University, contextualized the broader implications of these studies. Clonal hematopoiesis serves as a pivotal intersection connecting aging biology, cardiovascular disease, and cancer pathophysiology. Advances in understanding how inflammation and somatic genetic alterations coalesce to shape disease trajectories open novel pathways for precision prevention and treatment strategies that target both genetic drivers and inflammatory mediators.

The cumulative evidence spotlights colchicine as a cost-effective, well-tolerated pharmacological tool with potential to modify underlying disease mechanisms beyond symptomatic relief or secondary prevention. Its ability to attenuate inflammatory signaling pathways, notably those involving the NLRP3 inflammasome and interleukin-1 β, combined with the demonstrated suppression of CH clone expansion, positions colchicine at the forefront of next-generation cardio-oncology paradigms.

As our population ages and the burden of cardiovascular disease and hematologic malignancies escalates, identifying interventions that mitigate foundational biological causes takes on paramount importance. The synergy of genomic medicine, longitudinal biomarker monitoring, and repurposed anti-inflammatory agents heralds a transformative era in individualized cardiovascular and cancer risk management.

Further research aimed at delineating the molecular crosstalk between mutated hematopoietic clones and the vascular microenvironment will be critical in optimizing treatment algorithms. Trials designed to verify colchicine’s effects on CH populations across diverse demographics, as well as exploring combination therapies targeting multiple pathogenic axes, are eagerly anticipated. The integration of these discoveries into clinical practice offers the promise of dramatically altering the course of age-associated chronic diseases.

In summary, the groundbreaking research presented at ESC Congress 2025 and published in JACC reveals colchicine’s unprecedented role in modulating clonal hematopoiesis, particularly mutations in TET2, which are intimately tied to cardiovascular disease and malignancy risk. These findings highlight innovative pathways to combat the intertwined epidemics of aging, inflammation, blood cancer, and heart disease, providing hope for novel preventative and therapeutic strategies that address the root causes of morbidity and mortality in elderly populations.

Subject of Research: Effects of low-dose colchicine on clonal hematopoiesis and cardiovascular disease risk in elderly populations

Article Title: Low-Dose Colchicine Attenuates Clonal Hematopoiesis Expansion and Reduces Cardiovascular Risk: Insights from the LoDoCo2 Trial Subanalysis

News Publication Date: Not explicitly stated, presented at ESC Congress 2025

Web References:

• American College of Cardiology
• Journal of the American College of Cardiology (JACC)

Keywords: Clonal hematopoiesis, colchicine, cardiovascular disease, TET2 mutation, DNMT3A, ASXL1, inflammation, aging, hematologic malignancies, LoDoCo2 trial, anti-inflammatory therapy, cardiovascular risk reduction

Disulfidptosis constitutes a distinct form of regulated cell death, fundamentally different from apoptosis, necroptosis, or ferroptosis, distinguished by its reliance on intracellular disulfide bond dynamics. This pathway involves aberrant disulfide bond formation leading to cellular collapse and death, a process intricately tied to redox imbalances within tumor cells. The study’s comprehensive scope addresses a vital knowledge gap, providing the first pan-cancer exploration of genes related to this novel death mechanism, referred to collectively as disulfidptosis-related genes (DRGs).

Utilizing data from The Cancer Genome Atlas (TCGA), the research team implemented an integrative multi-omics approach to unravel the alterations in DRGs at genomic and epigenetic levels. They detected significant variations in gene expression patterns, copy number alterations, and DNA methylation profiles, which collectively influence how tumor cells regulate disulfidptosis. These molecular disruptions were not uniform but displayed pronounced heterogeneity across cancer types, underscoring the complexity of disulfidptosis regulation in distinct tumor contexts.

Central to this investigation was the construction of a disulfidptosis-related signature (DFRS), derived from advanced LASSO regression modeling combined with multivariate Cox proportional hazards analysis. This signature encapsulates the prognostic power of DRGs, stratifying patients according to risk and survival outcomes with remarkable precision. A high DFRS score consistently correlated with poorer prognosis, emphasizing its potential as a robust biomarker for clinical decision-making.

Beyond prognostication, the DFRS demonstrated a striking association with the tumor immune microenvironment. Tumors with elevated DFRS scores exhibited distinct immune infiltration patterns, characterized by an immunosuppressive milieu that likely impedes effective anti-tumor immunity. This intricate interplay suggests that disulfidptosis not only shapes tumor cell fate but also modulates the surrounding immune landscape, influencing tumor progression and resistance to immunotherapies.

Intriguingly, the study highlights the predictive capacity of the DFRS concerning therapeutic responsiveness. Patients exhibiting higher DFRS scores showed differential sensitivity to immune checkpoint inhibitors and conventional treatments, raising the prospect of utilizing disulfidptosis-related markers to personalize therapy. This aligns with a growing trend in oncology, where molecular signatures guide the selection and optimization of therapeutic regimens.

At the signaling level, disulfidptosis intersects with pivotal oncogenic pathways, including PI3K/AKT, MAPK, and p53 networks. Such crosstalk consolidates the role of disulfidptosis in tumor biology, integrating metabolic stress responses with cell death machinery. Targeting these interconnected pathways could potentiate the induction of disulfidptosis in resistant cancer cells, thereby overcoming therapeutic resistance.

The research further delves into epigenetic landscapes, revealing how DNA methylation patterns in DRGs modulate their expression and, consequently, disulfidptosis susceptibility. Aberrant methylation commonly silences tumor suppressor genes, but in the context of DRGs, it may either promote or inhibit the cell death pathway depending on specific gene targets. This nuanced epigenetic regulation opens avenues for demethylating agents or other epigenetic therapies to restore disulfidptosis in malignancies.

Importantly, the authors profile the heterogeneity of the TME across tumor types and correlate it with disulfidptosis dynamics. The TME encompasses not only immune cells but also fibroblasts, extracellular matrix, and vascular components, all of which orchestrate tumor progression. Understanding how disulfidptosis-related processes reshape this environment offers a holistic view of tumor ecology and potential vulnerabilities.

The study’s methodological rigor stands out, integrating large-scale genomic data with sophisticated bioinformatic models to yield actionable insights. This approach exemplifies the power of systems biology to dissect complex cancer phenotypes and identify convergent vulnerabilities amenable to therapeutic exploitation. By placing disulfidptosis at the crossroads of cancer genomics, immunology, and therapy, the research paves the way for innovative treatment strategies.

From a translational perspective, these findings suggest that modulating disulfidptosis could complement existing therapies such as checkpoint blockade and targeted kinase inhibitors. Pharmacologic agents designed to enhance disulfidptosis or to circumvent resistance mechanisms hold promise to improve patient outcomes, particularly for tumors with traditionally poor prognosis.

Moreover, the identification of DRG expression patterns as biomarkers enables early stratification of patients, facilitating timely intervention and personalized care. Precision oncology’s future increasingly relies on multifaceted signatures like DFRS to decode tumor behavior and predict therapeutic success.

The implications extend beyond prognosis and therapy. By elucidating the biology of disulfidptosis, the study contributes fundamentally to cell death research, expanding the repertoire of regulated death modalities and their relevance in human disease. This foundational knowledge is essential for conceptualizing novel drug targets and understanding cancer cell vulnerabilities.

Notably, the authors emphasize the necessity of further experimental validation and clinical trials to translate these discoveries into clinical practice. The interplay between disulfidptosis and the TME is undeniably complex, warranting in-depth mechanistic studies and the development of reliable assays for clinical monitoring.

In summary, this landmark research underscores disulfidptosis as a pivotal mechanism in cancer pathophysiology, intimately linked to the tumor microenvironment, patient prognosis, and therapeutic response. By harnessing its potential, future oncology treatments may achieve higher specificity and efficacy, marking a paradigm shift in how we approach cancer management globally.

As the oncology community continues to unravel the intricacies of tumor biology, disulfidptosis emerges as a critical frontier, promising to refine our understanding and treatment of cancer in the years to come.

Subject of Research: Disulfidptosis and its interaction with the tumor microenvironment across multiple types of cancer, focusing on prognosis and therapeutic response.

Article Title: Interplay of disulfidptosis and the tumor microenvironment across cancers: implications for prognosis and therapeutic responses

Article References:
Xu, S., Chen, Z., Chen, X. et al. Interplay of disulfidptosis and the tumor microenvironment across cancers: implications for prognosis and therapeutic responses. BMC Cancer 25, 1113 (2025). https://doi.org/10.1186/s12885-025-14246-1

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14246-1